SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Breast cancer research and treatment.
Times cited: 3
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Times cited: 1262